K
Kenneth J. Pienta
Researcher at Johns Hopkins University School of Medicine
Publications - 751
Citations - 72579
Kenneth J. Pienta is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 127, co-authored 671 publications receiving 64531 citations. Previous affiliations of Kenneth J. Pienta include Rutgers University & Harper University Hospital.
Papers
More filters
Journal ArticleDOI
Drug discovery in prostate cancer mouse models
TL;DR: Overall, mouse modeling is an essential part of prostate cancer research and drug discovery and emerging technologies and better and ever-increasing forms of communication are moving the field in a hopeful direction.
Journal ArticleDOI
Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape.
Ke-Chih Lin,Gonzalo Torga,Amy Wu,Joshua D. Rabinowitz,Wesley J Murray,James C. Sturm,Kenneth J. Pienta,Robert H. Austin +7 more
TL;DR: The microfluidic cell culture device is improved and used to probe adaption and evolution dynamics in prostate cancer cell metapopulations under a stress landscape of a chemotherapeutic drug (docetaxel).
Journal ArticleDOI
Radiation Therapy Oncology Group 0521: A Phase III Randomized Trial of Androgen Suppression and Radiation Therapy Versus Androgen Suppression and Radiation Therapy Followed by Docetaxel/Prednisone for Localized, High-Risk Prostate Cancer
Journal ArticleDOI
Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers.
TL;DR: Targeting a specific aspect of this tumor-promoting ecosystem engineering, such as blocking efferocytosis by M2-like macrophages, may improve the response to standard-of-care anticancer therapies.
Journal ArticleDOI
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
Matthew P. Deek,Kekoa Taparra,Dyda Dao,Luanna Chan,Ryan Phillips,R.W. Gao,Eugene D. Kwon,Curtiland Deville,Danny Y. Song,Stephen Greco,Michael A. Carducci,Mario A. Eisenberger,Theodore L. DeWeese,Samuel R. Denmeade,Kenneth J. Pienta,Channing J. Paller,Emmanuel S. Antonarakis,Kenneth R. Olivier,Sean S. Park,Bradley J. Stish,Phuoc T. Tran,Phuoc T. Tran +21 more
TL;DR: After MDT, the majority of patients have long-term control or oligoprogression (class I or II).